Accuray Incorporated (ARAY) 股票分析

公司概述

Accuray Incorporated specializes in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems used for tumor treatment across a global footprint including the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. Operating within the Healthcare sector as a Medical Devices industry participant, the company focuses on high-precision equipment essential for oncology care. The firm employs 990 individuals to support its operations and maintains a market capitalization of $50.01M alongside annual revenue of $436.97M. These valuation and revenue figures indicate that the company currently operates with a relatively small market capitalization relative to its revenue base, suggesting a market-to-book dynamic where the equity value is significantly lower than the asset base, which is atypical for a firm with nearly half a billion dollars in trailing twelve-month sales.

财务健康

Accuray Incorporated reported revenue of $436.97M for the trailing twelve months, yet posted a net income of -$35,622,000 and an EBITDA of -$1,700,000. The substantial gap between the positive revenue of $436.97M and the significant negative net income reveals a cost structure where operating expenses and other deductions far exceed gross profits, resulting in an overall loss. The company generated free cash flow of -$803,500, indicating a negative cash generation capability that constrains financial flexibility and requires reliance on external capital or existing cash reserves to fund operations. Profitability is further eroded by a gross margin of 27.8%, an operating margin of -5.4%, and a profit margin of -8.2%, with the negative operating and profit margins demonstrating that the company is currently unprofitable at the operational and bottom-line levels. On the balance sheet, the company holds $41.30M in cash against $174.23M in debt, resulting in a debt-to-equity ratio of 326.14, which signifies a highly leveraged position rather than a conservative one. Liquidity analysis shows a current ratio of 1.47, suggesting the company possesses enough current assets to cover short-term liabilities, though the margin is tight given the heavy debt load. Return on equity stands at -70.3% and return on assets is -1.2%, metrics that reveal management has yet to generate positive returns on shareholder capital or the total asset base, highlighting significant challenges in operational effectiveness.

估值评估

The company exhibits a P/E ratio (TTM) listed as N/A due to negative earnings, while the forward P/E is calculated at -14.03, reflecting the market's pricing of future earnings expectations based on current negative performance. The price-to-book ratio is 0.94, indicating that the market values the company at approximately 94% of its book value, suggesting no premium over assets but also implying that the stock trades at a discount relative to the net asset value. Alternative valuation metrics such as the price-to-sales ratio of 0.11 and an EV/EBITDA of -107.61 provide perspective on valuation multiples, where the extremely high negative EV/EBITDA underscores the depth of current losses and the lack of traditional earnings-based valuation support. Regarding trading ranges, the stock has a 52-week high of $2.10 and a 52-week low of $0.33, meaning the current market price sits within this volatility band but trades at a significant discount relative to the recent highs. The beta value of 1.32 indicates that the stock's price volatility is 32% higher than the broader market, exposing investors to amplified swings in share price compared to the general equity market.

Growth & Income

Revenue growth year-over-year is recorded at -12.0%, while earnings growth is N/A due to the lack of positive earnings in the prior period, implying that the company is currently contracting in terms of top-line sales without the benefit of earnings expansion. As a non-dividend payer, the company does not distribute a dividend yield, maintaining a payout ratio of 0.0%, which means all available earnings are theoretically retained for reinvestment into growth initiatives rather than being distributed to shareholders. This reinvestment strategy is critical given the negative cash flow and losses, as the company must channel resources back into R&D or operations to eventually achieve profitability. The overall growth and income profile is characterized by revenue contraction, negative earnings, and zero dividend distribution, presenting a high-risk, high-volatility investment scenario driven by the need to reverse the negative growth trajectory and restore profitability before any income generation can occur.